Search Results for keywords:"Artificial Intelligence"

The Bureau of Industry and Security (BIS) of the U.S. Department of Commerce announced a virtual public briefing on January 15, 2025, for a new rule titled "Framework for Artificial Intelligence Diffusion." This rule adjusts the controls on the export of advanced computing integrated circuits and introduces a new control on AI model weights to protect U.S. national security and foreign policy. People interested in attending must register by 9 a.m. EST on the same day. The rule also includes new license exceptions to help safely export these technologies to approved destinations.

The Executive Order 14179 aims to remove barriers to American leadership in artificial intelligence (AI). It emphasizes the importance of AI systems being free from bias and promotes policies to secure the United States' position as a global leader in AI. The order calls for developing an action plan to enhance America's AI dominance and revokes previous policies that hinder innovation. It requires various presidential advisors and agency heads to coordinate efforts to align current practices with this new policy, ensuring they support national security and economic competitiveness.

The National Security Commission on Artificial Intelligence announced a virtual public meeting that will take place on March 1, 2021, from 12:00 p.m. to 1:00 p.m. EST. The meeting aims to finalize and approve the Commission's recommendations on artificial intelligence for submission to Congress and the Executive Branch. The public can attend this open meeting by registering on the Commission's website, and written comments can be submitted via email. Members of the media are requested to RSVP to the Commission's press office.

The National Institute of Standards and Technology (NIST) announced that the National Artificial Intelligence Advisory Committee (NAIAC) will hold a virtual meeting on January 28, 2025. The meeting aims to report findings from working groups, propose actionable recommendations, and hear public briefings. Public registration is necessary to access the web conference, and details will be available on the NIST website. People can also submit public comments on the agenda, which will be accessible on the website.

The Administrative Conference of the United States has adopted three key recommendations. The first focuses on the use of algorithmic tools in regulatory enforcement, offering guidance on balancing efficiency with ethical concerns. The second recommendation emphasizes enhancing public engagement in agency rulemaking, especially when the usual notice-and-comment procedures are bypassed. The third recommendation suggests expanding nonlawyer assistance and representation in agency adjudications to ensure fair access for all individuals involved in legal and administrative processes.

The National Institutes of Health (NIH) announced a closed meeting for the National Institute of Allergy and Infectious Diseases Special Emphasis Panel. This meeting, set for January 7, 2025, will focus on reviewing and evaluating contract proposals related to using artificial intelligence to enhance clinical microscopy for diagnosing infectious diseases. Due to confidential matters concerning trade secrets and personal privacy, the meeting will not be open to the public, and it will take place virtually at the NIH's Rockville, MD location.

The Department of Veterans Affairs (VA) announced that the National Academic Affiliations Council (NAAC) will hold a public meeting in Washington, DC, on March 26-27, 2025. The Council will discuss various topics such as workforce pathways for mental health trainees, loan repayment, scholarships, and updates on Artificial Intelligence in VA. On the second day, there will be public comments. The public can attend and participate in the meeting, with contact information provided for additional inquiries.

The Food and Drug Administration (FDA) has reorganized its Center for Drug Evaluation and Research (CDER), specifically within the Office of Medical Policy (OMP), which was approved by the Secretary of Health and Human Services on November 19, 2024. This reorganization aims to improve the FDA's ability to conduct its public health mission by enhancing its capacity to innovate in clinical trials, using tools such as Artificial Intelligence (AI) and Digital Health Technologies (DHTs). The Division of Clinical Trial Quality has been renamed to the Division of Clinical Innovations to support this focus. This restructuring is intended to foster collaboration, attract a diverse workforce, and modernize policy development to guide innovative drug development practices.

The Food and Drug Administration (FDA) has released draft guidance for the industry on using Artificial Intelligence (AI) to aid in regulatory decisions for drugs and biological products. This guidance explains how AI can be used to produce credible information or data regarding the safety, effectiveness, or quality of these products. It emphasizes a risk-based assessment framework for AI models and encourages early consultation with the FDA to ensure compliance and credibility. The guidance and its proposed recommendations are open for public comment until April 7, 2025, allowing stakeholders to contribute their views on the outlined framework and engagement options with the FDA.

The Executive Order, "Advancing United States Leadership in Artificial Intelligence Infrastructure," seeks to bolster AI development in the U.S. by encouraging the creation of domestic AI infrastructure. It aims to enhance national security and economic competitiveness while ensuring sustainable energy use and community support. The order outlines plans for collaboration between federal agencies and private sectors to construct AI data centers powered by clean energy, with the long-term goal of maintaining U.S. leadership in AI technology. It includes steps for expediting permits, addressing energy demands, supporting global AI infrastructure development, and ensuring that the growth of AI benefits both national interests and local communities.